Metformin reduces abortion in pregnant women with polycystic ovary syndrome

@article{Khattab2006MetforminRA,
  title={Metformin reduces abortion in pregnant women with polycystic ovary syndrome},
  author={S. Khattab and Iman Abdel Mohsen and Ismail Aboul Foutouh and Ashraf Ramadan and Mohamed Moaz and Hesham G. Al-Inany},
  journal={Gynecological Endocrinology},
  year={2006},
  volume={22},
  pages={680 - 684}
}
Background. Women with polycystic ovary syndrome (PCOS) are considered to be at increased risk of miscarriage. Since metformin has beneficial effects on the risk factors contributing to first-trimester abortion in PCOS patients, we hypothesized that metformin – owing to its metabolic, endocrine, vascular and anti-inflammatory effects – may reduce the incidence of first-trimester abortion in PCOS women. Materials and methods. A prospective cohort study was set up to determine the beneficial… 

Effects of Metformin on Pregnancy Outcomes in Women with Polycystic Ovary Syndrome during First Trimester

Good maternal outcomes in women with polycystic ovary syndrome who continued metformin during first trimester including decrease incidence of spontaneous miscarriage and gastrointestinal diabetes mellitus are found.

Continuation of Metformin Reduces Early Pregnancy Loss in Obese Pakistani Women with Polycystic Ovarian Syndrome

It was found that continuation of Metformin during pregnancy significantly reduces EPL in women with PCOS, suggesting that IR may play a significant role in EPL.

Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study

  • S. KhattabI. Mohsen M. Youssef
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2011
Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women.

Metformin throughout Pregnancy in Women with Polycystic Ovary Syndrome: Safety and Advantages

Metformin therapy in pregnancy reduces the otherwise high incidence of 1st trimester abortions, and gestational diabetes in PCOS women is tolerated well and is not found to be teratogenic.

The Effect of Metformin on Pregnancy Outcome Among Filipino Women with Polycystic Ovary Syndrome

In Filipino women with PCOS, continuous use of metformin during pregnancy reduces the rate of first trimester spontaneous abortion and the differences in neonatal outcomes did not achieve statistical significance.

Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome

Metformin treatment in women with PCOS throughout pregnancy could increase the possibility of term delivery, VD and reduce the risk of EPL, preterm labor, pregnancy complications such as GDM and PIH, with no serious side effects.

Effect of metformin on miscarriage in pregnant patients with polycystic ovary syndrome.

It seems that continuing metformin during the first trimester of pregnancy has beneficial effects in patients with PCOS.

Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome?

Evaluating pregnancy outcomes in women with PCOS who conceived while on metformin treatment, and continued the medication for a variable length of time during pregnancy found evidence to support the long‐term use of insulin‐sensitizing agents during pregnancy inadequate.

Use of metformin during pregnancy for women with polycystic ovary syndrome

The use of metformin throughout pregnancy is associated with decreased rates of preterm labour, GDM, and PIH, however, more randomised controls involving larger numbers of participants are required for more definitive results.

The efficacy of metformin in pregnant women with polycystic ovary syndrome: A meta-analysis of clinical trials

Metformin therapy throughout pregnancy decreased the OR of EPL, GDM, PE, and PD in pregnant PCOS women with no serious detrimental side effects.
...

References

SHOWING 1-10 OF 43 REFERENCES

Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome.

Metformin improves all surrogate markers of endometrial receptivity in PCOS patients, without difference between patients who had favourable or unfavourable reproductive outcome.

Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin.

Metformin therapy during pregnancy in women with PCOS was safely associated with reduction in SAB and in GD, was not teratogenic, and did not adversely affect birthweight or height, or height and weight, weight, and motor and social development at 3 and 6 months of life.

Outcome of clinical pregnancies after ovulation induction using metformin

No evidence of any adverse clinical effects when metformin is continued in the first trimester of women with PCOS following ovulation induction is found, and there was also no evidence of an increase in the rate of miscarriage or multiple pregnancy.

Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome.

The results suggest that hyperinsulinemia/insulin resistance may be responsible for low progesterone levels during the luteal phase in polycystic ovary syndrome women with PCOS by decreasing insulin secretion with metformin.

Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: management of infertility and prevention of inadvertent masculinization of a female fetus.

Although the possibility of fetal masculinization exists in the presence of severe maternal hyperandrogenism, there are presently no effective preventive measures when this is found in women with PCOS.

Metformin administration improves endothelial function in women with polycystic ovary syndrome.

Investigation of the endothelial status in young women with polycystic ovary syndrome using a simple and easily reproducible hemodynamic method combined with a biological marker found PCOS women were found to exhibit endothelial dysfunction compared with controls, which was reversed 6 months after metformin administration.

Pregnancy Loss, Polycystic Ovary Syndrome, Thrombophilia, Hypofibrinolysis, Enoxaparin, Metformin

Enoxaparin-metformin reduces pregnancy loss in women with PCOS with one or more previous SAB, who also have thrombophilia and/or hypofibrinolysis, which is 2.4-fold lower than previous gestations.

Predictors of endothelial dysfunction in young women with polycystic ovary syndrome.

Women with PCOS have significant endothelial dysfunction at an early age (i.e. early 20s), and largely independent of obesity, and may gain particular benefit from measures to improve endothelial function.

Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.

The decrease of serum CRP levels during metformin therapy is in accordance with the known beneficial metabolic effects of this drug and suggests that CRP or other inflammation parameters could be used as markers of treatment efficiency in women with PCOS.

Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome.

It is indicated that high concentrations of luteinising hormone during the follicular phase in women with polycystic ovaries have a deleterious effect on rates of conception and may be a causal factor in early pregnancy loss.